Stanford doctors help develop first FDA-approved gene-editing treatment
Stanford Daily - 2024-04-09T07:26:54.000Z

The FDA recently approved Casgevy, a gene-editing medical treatment which uses CRISPR/Cas9 technology to treat sickle cell disease. Casgevy, which two Stanford faculty members contributed to via drug development and FDA approval, is the first gene-editing medical treatment to recieve FDA approval. Read this story